Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kevin Benson

Urogynecology and Reconstructive Pelvic Surgery Sioux Falls, SD Medical Doctor

NPI 1649259227 CMS profile 347093

1500 W 22Nd St, Ste 402, Sioux Falls, SD 57105

Open in the dashboard

General payments

$224,698

379 records reported · program years 2019–2025

Research payments

$49,798

Paid to them · 25 records reported · program years 2019–2025

Ownership & investment interest

$200,000

4 holdings reported · through program year 2025

Research they led as principal investigator

$1,247,329 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Kevin Benson of Sioux Falls, SD is reported in the CMS Open Payments database as having received $224,698 across 379 general payments and $49,798 in research payments paid to them. Separately, studies naming them as principal investigator received $1,247,329 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $200,000 across 4 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,609 27
2024 General $19,806 32
2023 General $47,107 78
2022 General $20,216 44
2021 General $34,301 68
2021 Research $4,923 4
2020 General $31,817 46
2020 Research $11,453 7
2019 General $60,840 84
2019 Research $33,422 14
2025 Ownership $50,000 1
2024 Ownership $50,000 1
2023 Ownership $50,000 1
2022 Ownership $50,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Benson
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Kevin Benson were reported at $10,609. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Kevin Benson Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $60,840 $358 $132–$1,270 $163
2020 $31,817 $198 $86–$642 $114
2021 $34,301 $361 $118–$1,182 $132
2022 $20,216 $410 $128–$1,175 $149
2023 $47,107 $434 $152–$1,344 $160
2024 $19,806 $494 $193–$1,331 $164
2025 $10,609 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $107,395 98 payments
  2. Medtronic, Inc. $67,145 124 payments
  3. Medtronic USA, Inc. $23,615 51 payments
  4. AbbVie, Inc. $11,576 31 payments
  5. Allergan Inc. $8,414 30 payments
  6. Axonics Modulation Technologies, Inc. $4,973 12 payments
  7. Nalu Medical, Inc. $800 1 payment
  8. Bluewind Medical $271 6 payments
  9. Coloplast Corp $194 12 payments
  10. Astellas Pharma US Inc $99 6 payments
  11. Other $216 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $108,383 58 payments
  2. Consulting Fee $91,069 63 payments
  3. Travel and Lodging $17,442 56 payments
  4. Food and Beverage $7,761 201 payments
  5. Gift $43 1 payment
Products named General payments · program years 2019–2025
  1. INTERSTIM Sacral Nerve Stimulation $40,049 92 payments
  2. SOLYX Pelvic Organ Prolapse $34,336 17 payments
  3. Solyx SIS System $33,585 39 payments
  4. INTERSTIM Sacral Nerve Stimulation $23,547 48 payments
  5. GENERAL PELVIC ORGAN PROLAPSE $13,218 5 payments
  6. SOLYX Pain Management $12,488 8 payments
  7. BOTOX Neuroscience $7,150 2 payments
  8. GENERAL - PELVIC ORGAN PROLAPSE $4,163 3 payments
  9. BOTOX Urology $3,700 3 payments
  10. BOTOX Urology $3,444 26 payments
  11. Other $20,560 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Coloplast Corp $48,658 24 payments
  2. Medtronic, Inc. $1,140 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

948

Median for Undefined Physician type: 319

Drug cost

$80,531

Median for Undefined Physician type: $28,032

Branded share of claims

26.4%

Median for Undefined Physician type: 24.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 124 $50,483
Estradiol Generic 204 $17,408
Mirabegron Er Mirabegron Brand 12 $3,552
Cephalexin Generic 272 $1,825
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 67 $1,753
Clobetasol Propionate Generic 42 $1,702
Trospium Chloride Er Trospium Chloride Brand 12 $1,186
Cholestyramine Cholestyramine (With Sugar) Brand 17 $1,051
Fluconazole Generic 56 $562
Trospium Chloride Generic 16 $415

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 138 Part D prescribers listed as Undefined Physician type; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$264,478

Of which drugs: $29,448

Medicare patients

613

Average age 73

Services billed

7,926

613 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 57%
Depression 32%
Osteoporosis 24%
Diabetes 23%
Ischemic heart disease 22%
Chronic kidney disease 21%
Heart failure 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 23 5,900 $29,422

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $190
$190 — 5,900

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

404 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in South Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record